BREAST CANCER
![Foto de BREAST CANCER](/img/grupo.png)
![Foto de Hospital Universitario Central de Asturias](/img/noimage_org.png)
Hospital Universitario Central de Asturias
Oviedo, EspañaPublications in collaboration with researchers from Hospital Universitario Central de Asturias (9)
2023
2019
-
Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients
Aging, Vol. 11, Núm. 9, pp. 2874-2888
-
Neoadjuvant metformin added to systemic therapy decreases the proliferative capacity of residual breast cancer
Journal of Clinical Medicine, Vol. 8, Núm. 12
-
The C allele of ATM rs11212617 associates with higher pathological complete remission rate in breast cancer patients treated with neoadjuvant metformin
Frontiers in Oncology, Vol. 9, Núm. MAR
2018
-
A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: The METTEN study
Oncotarget, Vol. 9, Núm. 86, pp. 35687-35704
2010
-
Erratum: Current controversies in the management of breast cancer (Clinical and Translational Oncology 12:4 (278-286))
Clinical and Translational Oncology
-
Supportive care for patients with early breast cancer
Clinical and Translational Oncology, Vol. 12, Núm. 1, pp. 32-42
2008
-
Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer
Cancer Treatment Reviews, Vol. 34, Núm. 8, pp. 701-709
2007
-
Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials
Cancer Treatment Reviews, Vol. 33, Núm. 5, pp. 474-483